SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is experiencing extreme volatility driven by a massive short squeeze, with the community fiercely debating whether the token is a legitimate ecosystem-building project or a coordinated pump-and-dump scheme. The discourse is hyper-polarized, featuring intense frustration from those suffering losses alongside aggressive promotion from participants banking on potential further upside and upcoming event catalysts.

Aave is a decentralized money market protocol where users can lend and borrow cryptocurrency across 20 different assets as collateral. The protocol has a native token called AAVE, which is also a governance token that lets the community decide the direction of the protocol in a collective manner. Lenders can&nbsp;earn interest by providing liquidity to the market, while borrowers can borrow by collateralizing their cryptoassets to take out loans from the liquidity pools.

AAVE

AAVE is drawing significant community attention as traders highlight its strong fundamental metrics and the potential for a long-term breakout within the DeFi sector. Discussions are currently dominated by comparisons to other lending protocols and active debates regarding its long-term accumulation strategy and price potential in the coming cycles.

TokenOS is the world’s most advanced AI-powered Web3 development platform, designed to turn natural language prompts into fully functional, production-ready blockchain applications. From simple tokens and memecoins to complex DeFi protocols, TokenOS automates the creation, deployment, and auditing of smart contracts and dApps with enterprise-grade reliability. By combining advanced language models with blockchain infrastructure, TokenOS removes the barriers of technical expertise, making Web3 development accessible to everyone. With instant deployment, built-in security best practices, and cross-chain support on the roadmap, TokenOS empowers entrepreneurs, developers, and creators to launch tokenized businesses and decentralized applications in seconds.

TokenOS AI

TokenOS AI is gaining momentum as investors highlight its infrastructure as a dedicated blockchain for autonomous AGI agents, focusing on its Proof-of-Work BlockDAG architecture and unique energy-staking model. Community members are actively positioning the project as a high-potential AI utility play, emphasizing its fair launch and the growing integration of on-chain machine-to-machine economies.

"What's Updog?" is a Community Led token.

UpDog

The UpDog community is rallying around the ticker through active social engagement and a consistent "smells like UpDog" branding strategy. Members are focusing on Solana-based ecosystem growth, community-led poker events, and active whale accumulation to drive long-term project momentum.

NioCorp Developments Ltd. engages in the evaluation, acquisition, exploration, and development of mineral deposits. It focuses on a super alloy materials project in Nebraska for producing niobium, scandium, and titanium. The company was founded on February 27, 1987, and is headquartered in Centennial, CO.

NioCorp Developments Ltd

NioCorp Developments Ltd. is trending as investors monitor ongoing project updates, including portal construction and the anticipated feasibility study, while actively debating the company's timeline for securing critical EXIM bank loan financing. The community remains hyper-focused on the broader geopolitical push for domestic critical mineral supply chains, often comparing NioCorp's strategic assets to industry peers and speculating on future government support catalysts.

Asteroid Shiba is inspired by a real-life event where a Shiba Inu plush toy named "Asteroid" served as a zero-gravity indicator during the Polaris Dawn mission. This connection to space travel gives it a narrative that's both whimsical and grounded in a tangible event, differentiating it from other meme coins which might rely solely on internet culture or celebrity endorsements.  The coin's mascot, the zero-gravity Shiba Inu, was designed by a young cancer survivor, Liv Perrotto, adding a layer of emotional connection and human interest story that's rare in the crypto space. This backstory not only provides a unique selling point but also a community rallying point.

Asteroid Shiba

Asteroid Shiba is gaining momentum as community members speculate on its potential to capitalize on the community-takeover trend and draw attention away from established meme coins. Supporters are actively discussing the project's thematic ties to space-related narratives and its perceived ability to revitalize interest in the sector.

What Is Request (REQ)? The Request (REQ) utility token, launched in 2017, ensures the performance and stability of the Request Network. The Request Network itself is an Ethereum-based decentralized payment system where anyone can request a payment and receive money through secure means. It removes the requirement for third parties in order to provide a cheaper, more secure payment solution that works with all global currencies.  When a user creates a request for payment, they define to which address the payment needs to be allocated and what the amount is. The user can also define the terms and conditions of the payment, upgrading a simple request into an invoice. Once this is completed, the user can share their request to be paid by their counterparty.  Every step is documented and stored on the Request network, allowing everyone involved to easily keep track of all the invoices and payments for accounting purposes.  Request is also integrated with legislation across the world to remain compliant with the trade laws of each individual country.  Who Are the Founders of Request? The founders of Request are Christophe Lassuyt and Etienne Tatur.  Christophe Lassuyt is currently the chief financial officer at Request. Before this position, he co-founded MONEYTIS.  Etienne Tatur is the chief technical officer of Request. Prior to this, he also co-founded MONEYTIS and worked as a lead developer at QOBUZ, a music streaming service.  What Makes Request Unique? The payments on Request are performed by simply sending an invoice through the blockchain; the counterparty can then detect the request and pay it with one click in a peer-to-peer manner. The fact that the payments are push-generated instead of pull-generated is one of Request’s key advantages. There is no need for users to share their account information. The use of blockchain technology also eliminates the need for third-party processors, resulting in a reduction in transaction costs.  The Request Network leverages decentralized blockchains such as Ethereum and IPFS for an increased level of security, privacy and data ownership for the end-user. The platform does have transaction fees, which is a cost that is required to broadcast a change to the blockchain network. The transaction fees are used to incentivize miners to reach consensus on the state of the network.  REQ can be stored on wallets such as Metamask, MyEtherWallet, Ledger, imToken, Trezor, Atomic Wallet, Jaxx Liberty and Trust Wallet.  How Many Request (REQ) Coins Are There in Circulation? REQ is an ERC-20 token that can be spent to use the Request Network.  A portion of the REQ fee is burned at a rate that is determined by the current supply and the exchange rate with other currencies.  Request’s (REQ) circulating supply is at 999,912,165 REQ as of February 2021 and the maximum supply is 999,983,984 tokens.  How Is the Request Network Secured? REQ is an ERC-20 token based on the Ethereum platform. The requests made with REQ are stored on an immutable digital ledger. This ledger also serves as proof for all auditing purposes.

Request Network

Request Network is gaining traction on social media as investors reminisce about its historic holiday-season rallies, leading to intense speculation about a potential repeat performance. While some community members are frustrated by stagnant price action and perceived lack of company communication, others are actively accumulating tokens, citing its low circulating supply and real-world payment utility as catalysts for a future breakout.

Newcourt Acquisition Corp. is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on February 25, 2021 and is headquartered in Oakland, CA.

Psyence Biomedical Ltd.

Psyence Biomedical Ltd. (PBM) is experiencing significant volatility and trending status driven by anticipation of a U.S. executive order to expedite research into ibogaine for mental health. The community is actively debating the stock's potential for a major short squeeze due to its extremely low float, with many bulls expecting parabolic price action while skeptics warn of fundamental weakness and potential dilution.

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic is experiencing significant community volatility and engagement, driven by ongoing debates over exchange listings, anticipated ecosystem upgrades, and speculation regarding its long-term potential for recovery. Investors remain divided, with many actively discussing the token's burn mechanisms and future utility while others express skepticism, maintaining high interest despite the significant challenges the project faces.

American Exceptionalism Acquisition Corp. A is a blank check company. It was created for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination. The company was founded on July 11, 2025 and is headquartered in Menlo Park, CA.

American Exceptionalism Acquisition Corp. A - Ordinary Shares - Class A

American Exceptionalism Acquisition Corp. A

Investors are actively buzzing over the latest SPAC from Chamath Palihapitiya, debating whether the vehicle will target high-profile companies in sectors like AI, defense, or energy. The community remains divided, with supporters anticipating a massive, hype-driven run while skeptics warn of past SPAC failures and the potential for a long period of sideways trading until a deal is announced.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wealth Effects LLC Reduces Stock Holdings in Arrowhead Pharmaceuticals, Inc. $ARWR

Wealth Effects LLC lessened its holdings in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 14.9% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 143,300 shares of t...

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Cross Above 200-Day Moving Average   - Here's Why

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Crosses Above Two Hundred Day Moving Average - Should You Sell...

Aberdeen Group plc Sells 234,498 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR

Aberdeen Group plc cut its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 45.0% during the 4th quarter, according to its most recent disclosure with the...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the eleven analysts that are presently covering the firm...

Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiologys 75th Annual Scientific Session and Expo

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced long-term efficacy and safety data from a two-year long open-label extension (OLE) study of investigational plozasiran supporting its...

<ul class="summary-bullets"><li>Wave said earlier on Thursday that individuals administered a single 240 mg dose of WVE-007 showed a body weight reduction of 0.9% in the early stage portion of its trial.</li><li>Jones Research attributed WVE’s selloff on Thursday to the low total weight loss at six months, 0.9% versus hopes for 2% or 3%.</li><li>Unlike traditional GLP-1 drugs that often lead to muscle loss, Arrowhead’s obesity candidates, ARO-INHBE and ARO-ALK7, aim to reduce body fat, while specifically preserving lean muscle mass.</li></ul> Shares of Arrowhead Pharmaceuticals Inc. (ARWR) fell nearly 2% on Thursday before paring back losses after Wave Life Sciences (WVE) announced mixed data from the early stage portion of its trial evaluating its investigational drug WVE-007 in individuals with obesity.Leerink analyst Mani Foroohar said that they are not surprised to see ARWR stock down as material obesity value is baked in at Arrowhead’s $8.5 billion market cap. The firm has a ‘Market Perform’ rating on Arrowhead shares.Wave said earlier on Thursday that individuals administered a single 240 mg dose of WVE-007 showed a body weight reduction of 0.9% in the early stage portion of the trial, with clinically meaningful reductions in visceral fat and waist circumference, after six months. The investigational drug was well tolerated to date up to 600 mg with no treatment discontinuations, the company said.<a href="https://stocktwits.com/symbol/WVE">WVE shares</a> traded 50% lower at the time of writing. &nbsp;<h2 class="st-heading-2">Why The WVE Selloff?</h2>Jones Research attributed WVE’s selloff to the low total weight loss at six months, 0.9% versus hopes for 2% or 3%. The firm believes that while WVE-007 may not be competitive to GLP-1 category weight loss drugs in the general population, there is still a chance for utility in the elderly or patients with metabolic disease.Jones Research has a ‘Buy’ rating on Wave Life with a $35 price target.Leerink analyst Joseph Schwartz, meanwhile, said that the firm likes the continued improvement in visceral fat reduction at 240 mg after six months, as well as the larger reduction on waist circumference and measurable body weight reduction. The stock's reaction premarket seems to remove all value for WVE-007, which is "very overdone," the firm said. Leerink has an ‘Outperform’ rating on WVE shares.<h2 class="st-heading-2">Arrowhead’s Obesity Pipeline</h2>Unlike traditional GLP-1 drugs that often lead to muscle loss, Arrowhead’s obesity candidates, ARO-INHBE and ARO-ALK7, aim to reduce body fat while specifically preserving lean muscle mass.While comparisons between Wave and Arrowhead data are impaired by small numbers of patients, differences in baseline, and other factors, the greater than 50% fall in Wave's stock price "highlights the degree of optimism baked into INHBE expectations" and brings questions related to Arrowhead "back to center stage," Foroohar told investors, as per TheFly.BofA, meanwhile, lowered the firm's price target on Arrowhead to $81 from $84 and kept a ‘Buy’ rating on the shares. The analyst said that Wave’s update appears largely priced in.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around ARWR stock improved from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume increased from ‘low’ to ‘high’ levels.<a href="https://stocktwits.com/symbol/ARWR">ARWR stock</a> has more than quadrupled over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/htz-stock-soars-tsa-delays-airports-spike-in-car-rental-searches/cZ3sTFCRIke">HTZ Stock Soars After TSA Delays At Airports Reportedly Result In Spike In Car Rental Searches</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Arrowhead Pharmaceuticals logo is seen displayed on a smartphone screen.

ARWR Stock Slid Lower Today — What Does Wave Life Sciences Have To Do With It?

Leerink analyst Mani Foroohar said that they are not surprised to see Arrowhead Pharmaceuticals’ stock down as material obesity value is baked in at the company’s $8.5 billion market cap.

Equity

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Gap Down   - What's Next?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Gap Down - Here's What Happened...

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Receives "Buy" Rating from HC Wainwright

HC Wainwright reiterated a "buy" rating and issued a $100.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Wednesday...

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Up 8.6% - Here's What Happened

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Trading Up 8.6% - Time to Buy...

Arrowhead Pharmaceuticals, Inc. $ARWR Shares Sold by Nordea Investment Management AB

Nordea Investment Management AB lowered its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 12.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 324,251 shares of the biotechnology comp...

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Current Price	$69.51
Prev Close	$67.98
Open	$69.77
Dividend Yield	0.00%
50-Day Moving Average	$61.93
Beta	1.57
Avg. Volume	2.56M
PE Ratio	45.19

52-Week High	$76.76
52-Week Low	$10.95
Market Capitalization	$9.73B
EPS (Annual)	-$0.0122
Price to Book	16.80
Revenue Per Employee	$1.17M

ARWR
Arrowhead Pharmaceuticals Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ARWR News

ARWRArrowhead Pharmaceuticals Inc.